424(b)(3)
Filed pursuant to rule 424(b)(3)
Registration Statement No. 333-135029
PROSPECTUS SUPPLEMENT NO. 5
(TO PROSPECTUS DATED AUGUST 21, 2006)
PROSPECTUS
UP TO 1,550,134 SHARES OF
SPECTRUM PHARMACEUTICALS, INC.
COMMON STOCK
This prospectus supplement no. 5 relates to the offer and sale of up to 1,550,134 shares of our common stock by the selling stockholders named in the prospectus dated August 21, 2006, as supplemented by prospectus supplement no. 1 dated October 22, 2007, no. 2 dated March 31, 2008, no. 3 dated April 20, 2009 and no. 4 dated July 14, 2011 (the “Prospectus”). This prospectus supplement no. 5 should be read in conjunction with the Prospectus.
In connection with our 2006 acquisition of all the oncology drug assets of Targent, LLC, as the successor to Targent, Inc. (“Targent”), Targent is eligible to receive contingent consideration, in the form of either cash or shares, upon the satisfaction of certain milestones. As a result of the satisfaction of one such milestone in 2011, we are issuing an aggregate of 577,367 shares of our common stock, as directed by Targent, to the individuals or entities named in the Selling Stockholders table below. Pursuant to this prospectus supplement no. 5, as required by the registration rights agreement with Targent, we are registering for resale 192,456 of those 577,367 shares. Other than the asset purchase agreement relating to the acquisition and transactions contemplated thereby, there are no material relationships between the Company and Targent or its stockholders.
The information appearing in the table below, as of the date hereof, supplements the information in the table appearing under the heading “Selling Stockholders” in the Prospectus. This table only provides beneficial ownership information with respect to selling stockholders who are receiving shares of our common stock in connection with the achievement of a milestone related to the acquisition of certain assets from Targent, as described above.
We prepared this table based on the information supplied to us by the selling stockholders named in the table and we have not sought to verify such information. Since the date on which the selling stockholder provided this information, the selling stockholder may have sold, transferred or otherwise disposed of all or a portion of the shares of common stock that he, she or it beneficially owns in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended, or pursuant to an existing resale registration statement.
                                         
    Shares of Common Stock             Shares of Common Stock  
    Beneficially Owned     Number of     Beneficially Owned  
    Before Offering     Shares     Following the Offering(1)  
            % of     of Common Stock             % of  
Name   Number     Class     Offered Hereby     Number     Class  
Robert F. Johnston
     534,096       * %     73,106       460,990       * %
Hephaestos II Trust UAD 12/31/1991 (2)
     152,980       *       20,207       132,773       *  
Lynn D. Johnston
     164,689       *       18,632       146,057       *  
11/6/1978 Trust F/B/O William Johnston (2)
     22,635       *       2,396       20,239       *  
William M. Johnston APT LLC (2)
     44,793       *       4,331       40,462       *  
William M. Johnston GST 6/1/2004 (2)
     13,527       *       1,816       11,711       *  

 

 

                                         
    Shares of Common Stock             Shares of Common Stock  
    Beneficially Owned     Number of     Beneficially Owned  
    Before Offering     Shares     Following the Offering(1)  
            % of     of Common Stock             % of  
Name   Number     Class     Offered Hereby     Number     Class  
Trust F/B/O Bradford Johnston 11/6/1978 (2)
     73,151       *       7,118       66,033       *  
Bradford D. Johnston GST dtd 1/29/02 (2)
     9,704       *       1,425       8,279       *  
Trust F/B/O Alexandra Johnston 11/06/78 (2)
     73,154       *       7,118       66,036       *  
Alexandra F. Johnston Trust DTD 2/25/2004 (2)
     9,704       *       1,425       8,279       *  
Targent Pharmaceuticals, LLC (3)
     118,229       *       21,335       96,894       *  
Seth Lederman
     11,734       *       2,117       9,617       *  
Eli R. Lederman
     104,334       *       9,959       94,375       *  
James Bell
     7,625       *       1,027       6,598       *  
Bayard Henry
     28,771       *       3,266       25,505       *  
Peter Melhado
     12,196       *       2,182       10,014       *  
Lysander, LLC (4)
     62,073       *       6,173       55,900       *  
Patrick Maguire
     2,919       *       428       2,491       *  
Ernest Mario
     36,928       *       3,397       33,531       *  
Stephen K. Carter
     5,326       *       428       4,898       *  
Gerold F.L. Klauer IRA
     24,909       *       3,656       21,253       *  
James Harpel
     6,228       *       914       5,314       *  
 
                                  
Total :
     1,519,705               192,456       1,327,249          
     
*  
less than 1%
 
(1)  
Assumes the sale by the selling stockholders of all of the shares of common stock available for resale under this prospectus supplement.
 
(2)  
Richard Johnston is a Trustee and holds the dispositive voting and investment power over the shares of common stock.
 
(3)  
Seth Lederman is the Managing Member and holds the dispositive voting and investment power over the shares of common stock.
 
(4)  
Stuart Davidson is a Member and holds the dispositive voting and investment power over the shares of common stock.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE “RISK FACTORS” IN OUR FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2010 AND OTHER DOCUMENTS INCORPORATED BY REFERENCE INTO THE PROSPECTUS.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is September 16, 2011.